Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Gentian Diagnostics - Grant of options

GENTRegulatory press release2026-11-06 10:27
Read the release
Moss, 6 November 2026

Reference is made to the annual general meeting 6 May 2025 where guidelines for
remuneration of executive personnel were approved. In accordance with these
guidelines the board of Gentian Diagnostics ASA has allocated a total of 485,000
options to key employees under the existing option program.

The following number of options have been allocated to primary insiders of
Gentian Diagnostics ASA:

Matti Heinonen, Chief Executive Officer: 100,000 options with a strike price of
NOK 60.00 and 100,000 options with a strike price of NOK 44.00. Following the
grant, Mr. Heinonen holds 15,569 shares and 300,000 options in the Company.

Njaal Kind, Group Chief Financial Officer: 50,000 options with a strike price of
NOK 60.00 and 50,000 options with a strike price of NOK 44.00. Following the
allocation Mr. Kind holds 32,194 shares and 240,670 options in the Company.

Aleksandra Havelka, Chief Scientific Officer: 20,000 options with a strike price
of NOK 44.00. Following the allocation Ms. Havelka hold 2,920 shares and 100,000
options in the Company.

Hanne Kristiansen, Vice President Commercial: 20,000 options with a strike price
of NOK 60.00 and 20,000 options with a strike price of NOK 44.00. Following the
allocation Ms. Kristiansen holds 1,023 shares and 40,000 options in the Company.

The right to exercise the options is vested over a period of 2 years, with 50%
of the options vesting by the end of each year as follows: (i) 50% of the
options granted, no earlier than 3 years after the allocation date, (ii) 50% of
the options granted, no earlier than 4 years after the allocation date at an The
options may also be exercised at expiry after 5 years.

Attached are the notifications of the transactions pursuant to the market abuse
regulation article 19. This information is subject to the disclosure
requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

For further information, please contact:
Njaal Kind CFO, Gentian Diagnostics ASA
E-mail: njaal.kind@gentian.no
Phone: +47 919 06 525
gnostics ASA \
E-mail: njaal.kind@gentian.no \
Phone: +47 919 06 525\